Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors allow efficient gene transfer and expression in the muscle; therefore, rAAVs represent a potential gene therapy vector for muscular dystrophies. For further investigations, we used a mouse muscular dystrophy model (gsg(-/-) mice) gamma-sarcoglycan, a subunit of the dystrophin-glycoprotein complex, is missing. gsg(-/-) mice develop progressive dystrophy representative of a severe human phenotype disease. We previously showed high levels and stable expression of gamma-sarcoglycan in myofibers after direct muscle injection into gsg(-/-) mice of a recombinant AAV vector (AAV.dMCK.gSG) carrying the gamma-sarcoglycan cDNA driven by a muscle-specific promoter (truncated version of muscle creatine kinase). Here, we show that when gamma-sarcoglycan expression is driven by the ubiquitous cytomegalovirus (CMV) promoter (AAV.CMV.gSG), lower levels of transgene expression are observed and are associated with a humoral response to gamma-sarcoglycan. When using an rAAV vector, expressing the highly immunogenic product gamma-galactosidase under the CMV promoter (AAV.CMV.LacZ), we measured a strong cellular and humoral immune response to the transgene after intramuscular injection into gsg(-/-) mice. This study suggests that restriction of transgene expression to the muscle is an important criterion for the treatment of muscular dystrophies and will aid in the design of protocols for gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to systemic immune suppression, preclinical studies pointed out the role of tissue-specific promoters in reducing immune responses against delivered transgene [232, 233].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [232]
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 2×
“To appreciate the contribution of endogenous transduction of antigen-presenting cells (APCs) by the rAAV, we compared an rAAV expressing g -sarcoglycan under the control of a muscle-specific promoter (truncated version of the muscle creatine kinase [MCK]) and the ubiquitous CMV promoter.”
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Yang, Y., Li, Q., Ertl, H. C., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,032 · cited 1×
“These vectors usually exhibit loss of expression 3 to 4 weeks after administration (Yang et al ., 1995b, 1996b; Tripathy et al ., 1996).”
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912 · cited 1×
“CMV. LacZ has been shown to allow long-term expression (greater than 1 year) of the marker protein without eliciting a cellular or humoral immune response to the vector-transduced cells (Xiao et al ., 1996; Fisher et al ., 1997).”
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Self-citationTripathy, S. K., Black, H. B., Goldwasser, E., & Leiden, J. M. (1996) · Nature Medicine · doi:10.1038/nm0596-545 · Cited by 628 · cited 1×
“These vectors usually exhibit loss of expression 3 to 4 weeks after administration (Yang et al ., 1995b, 1996b; Tripathy et al ., 1996).”
Sigal, L. J., Crotty, S., Andino, R., & Rock, K. L. (1999) · Nature · doi:10.1038/18038 · Cited by 578
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547 · cited 1×
“Transfection was carried out by the standard calcium phosphate precipitation method. rAAV vector preparations used in this study were purified by the CsCl gradient centrifugation process as described earlier (Fisher et al ., 1996).”
Self-citationDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 3×
“Regarding the immunogenicity of rAAV, previous studies have described rAAV vectors as nonimmunogenic, allowing sustained trans-gene expression on in vivo administration (Snyder, 1999). rAAV vectors expressing lacZ are capable of infecting dendritic cells (DCs), but are unable to transduce b -galactosidase ( b -Gal) ex…”
Self-citationYang, Y., Jooss, K. U., Su, Q., Ertl, H. C. J., & Wilson, J. M. (1996) · PubMed · Cited by 375
Self-citationEfficient lentiviral transduction of liver requires cell cycling in vivo
Park, F., Ohashi, K., Chiu, W., Naldini, L., & Kay, M. A. (2000) · Nature Genetics · doi:10.1038/71673 · Cited by 323
γ-Sarcoglycan Deficiency Leads to Muscle Membrane Defects and Apoptosis Independent of Dystrophin
Hack, A. A., Ly, C. T., Jiang, F., Clendenin, C. J., Sigrist, K. S., Wollmann, R. L., & McNally, E. M. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.142.5.1279 · Cited by 286
Self-citationYang, Y., Xiang, Z., Ertl, H. C., & Wilson, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7257 · Cited by 260 · cited 1×
“- CMV .gSG ), or under the control of a truncated muscle creatine kinase (dMCK) promoter the human g -sarcoglycan protein (Ad.dMCK .gSG ) have been previously described (Yang et al ., 1995a; Cordier et al ., 2000).”
Self-citationGreelish, J. P., Su, L. T., Lankford, E. B., Burkman, J. M., Chen, H., Konig, S. K., Mercier, I. M., Desjardins, P. R., Mitchell, M. A., Zheng, X. G., et al. (1999) · Nature Medicine · doi:10.1038/7439 · Cited by 212
Self-citationSnyder, R. O., Spratt, S. K., Lagarde, C., Bohl, D., Kaspar, B., Sloan, B., Cohen, L. K., & Danos, O. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.16-1891 · Cited by 211
The kinetics of rAAV integration in the liver
Miao, C. H., Snyder, R. O., Schowalter, D. B., Patijn, G. A., Donahue, B., Winther, B., & Kay, M. A. (1998) · Nature Genetics · doi:10.1038/ng0598-13 · Cited by 186
Isolation of Recombinant Adeno-Associated Virus Vector-Cellular DNA Junctions from Mouse Liver
Nakai, H., Iwaki, Y., Kay, M. A., & Couto, L. B. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5438-5447.1999 · Cited by 185 · cited 1×
“Integration into the host genome after in vivo transduction has been shown in the liver (Miao et al ., 1998; Nakai et al ., 1999), in hematopoietic progenitor cells (Fisher-Adams et al ., 1996), and in neurons (Wu et al ., 1998) as head-to-tail concatemers.”
Adenovirus and Adeno-Associated Virus Vectors
Lai, C. M., Lai, Y. K. Y., & Rakoczy, P. E. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053855 · Cited by 175
Gao, G., Qu, G., Burnham, M. S., Huang, J., Chirmule, N., Joshi, B., Yu, Q.-C., Marsh, J. A., Conceicao, C. M., & Wilson, J. M. (2000) · Human Gene Therapy · doi:10.1089/104303400750001390 · Cited by 174
Self-citationBrockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., & Engleman, E. G. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4724 · Cited by 165 · cited 1×
“Brockstedt et al. (1999) have looked at the immune response to ovalbumin after intraperitoneal, intravenous, sub-cutaneous, or intramuscular delivery of an rAAV encoding ovalbumin.”
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy
McNally, E. M., Duggan, D., Gorospe, J. R. M., Bönnemann, C. G., Fanin, M., Pegoraro, E., Lidov, H. G., Noguchi, S., Ozawa, E., Finkel, R. S., et al. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.11.1841 · Cited by 157
Self-citationMild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation.
McNally, E. M., Passos-Bueno, M.-R., Bönnemann, C. G., Vainzof, M., Moreira, E. S., Lidov, H. G. W., Othmane, K. B., Denton, P. H., Vance, J. M., Zatz, M., et al. (1996) · PubMed Central · Cited by 156
Self-citationWu, P., Phillips, M. I., Bui, J., & Terwilliger, E. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.7.5919-5926.1998 · Cited by 137 · cited 1×
“Integration into the host genome after in vivo transduction has been shown in the liver (Miao et al ., 1998; Nakai et al ., 1999), in hematopoietic progenitor cells (Fisher-Adams et al ., 1996), and in neurons (Wu et al ., 1998) as head-to-tail concatemers.”
Yang, Y., Greenough, K., & Wilson, J. M. (1996) · PubMed · Cited by 131
Self-citationManning, W. C., Paliard, X., Zhou, S., Pat Bland, M., Lee, A. Y., Hong, K., Walker, C. M., Escobedo, J. A., & Dwarki, V (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7960-7962.1997 · Cited by 122
Zhang, Y., Chirmule, N., Gao, G.-P., & Wilson, J. (2000) · Journal of Virology · doi:10.1128/jvi.74.17.8003-8010.2000 · Cited by 119
Self-citationrAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy
Li, J., Dressman, D. C., Tsao, Y., Sakamoto, A., Hoffman, E. P., & Xiao, X. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300830 · Cited by 114 · cited 1×
“ND, Not determined. been found (Greelish et al ., 1999; Li et al ., 1999; Xiao et al ., 2000a).”
Adeno-associated virus-mediated gene delivery
Snyder, R. O. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199905/06)1:3<166::aid-jgm34>3.0.co;2-z · Cited by 105 · cited 1×
“…of rAAV, previous studies have described rAAV vectors as nonimmunogenic, allowing sustained trans-gene expression on in vivo administration (Snyder, 1999). rAAV vectors expressing lacZ are capable of infecting dendritic cells (DCs), but are unable to transduce b -galactosidase ( b -Gal)…”
Fisher-Adams, G., Wong, K. J., Podsakoff, G., Forman, S., & Chatterjee, S. (1996) · Blood · doi:10.1182/blood.v88.2.492.bloodjournal882492 · Cited by 103
Cordier, L., Hack, A. A., Scott, M. O., Barton-Davis, E. R., Gao, G.-P., Wilson, J. M., McNally, E. M., & Sweeney, H. L. (2000) · Molecular Therapy · doi:10.1006/mthe.1999.0019 · Cited by 101
Self-citationXiao, X., Li, J., Tsao, Y.-P., Dressman, D., Hoffman, E. P., & Watchko, J. F. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1436-1442.2000 · Cited by 100 · cited 1×
“LacZ were derived from psub201 and contain the minigenes in place of AAV rep and cap genes. rep and cap functions were provided by trans -acting plasmid pTrans-600 trans (Xiao et al ., 2000).”
Targeting calcium cycling proteins in heart failure through gene transfer
del Monte, F., & Hajjar, R. J. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.026732 · Cited by 97
Comparison of the muscle fiber diameter and satellite cell frequency in human muscle biopsies
Maier, F., & Bornemann, A. (1999) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199905)22:5<578::aid-mus5>3.0.co;2-t · Cited by 71
Gene therapy for rheumatoid arthritis
Bessis, N., Doucet, C., Cottard, V., Douar, A. M., Firat, H., Jørgensen, C., Mezzina, M., & Boissier, M. (2002) · The Journal of Gene Medicine · doi:10.1002/jgm.325 · Cited by 69
Liu, Y., Santin, A. D., Mane, M., Chiriva-Internati, M., Parham, G. P., Ravaggi, A., & Hermonat, P. L. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/107999000312702 · Cited by 63
Effective adenovirus-mediated gene expression in adult murine skeletal muscle
Ishii, A., Hagiwara, Y., Saito, Y., Yamamoto, K., Yuasa, K., Sato, Y., Arahata, K., Shoji, S., Nonaka, I., Saito, I., et al. (1999) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199905)22:5<592::aid-mus7>3.0.co;2-2 · Cited by 35
Abina, M. A., Lee, M. G., Descamps, V., Cordier, L., Lopez, M., Perricaudet, M., & Haddada, H. (1996) · PubMed · Cited by 24
Self-citationThe Sarcoglycan Complex in Striated and Vascular Smooth Muscle
Wheeler, M. T., Allikian, M. J., Heydemann, A., & McNally, E. M. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.389 · Cited by 21
Self-citationMouse dystrophin enhancer preferentially targets lacZ expression in skeletal and cardiac muscle
Marshall, P. L., Chartrand, N., Repentigny, Y. D., Kothary, R., Pelletier, L., Mueller, R., & Worton, R. G. (2002) · Developmental Dynamics · doi:10.1002/dvdy.10080 · Cited by 9
Chirmule, N. B., Moffett, J., Dhagat, P., Tazelaar, J., & Wilson, J. M. (1999) · Human Gene Therapy · doi:10.1089/10430349950016564 · Cited by 8 · cited 2×
“b -Galactosidase histochemistry was analyzed in frozen sections (10 m m) as described previously (Chirmule et al ., 1999).”
Self-citationGene therapy: a strategy for the treatment of inherited muscle diseases?
Moisset, P.-A. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00052-2 · Cited by 5
Research works printed but not linked: 5
- ABINA M.A., 1996, Gene Ther., 3, 212
- BROCKSTEDT D.G., 1999, J. Appl. Biomater., 92, 67
- MCNALLY E.M., 1996, Am. J. Hum. Genet., 59, 1040
- YANG Y., 1996, Gene Ther., 3, 137
- YANG Y., 1996, Gene Ther., 3, 412
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“The role of tissue-specific promoters in reducing or abrogating immune responses to the transgene product has been demonstrated in the setting of animal models of muscular dystrophy.(136,137) The use of tissue-specific micro RNA elements to detarget transgene expression in DCs, first used in the context of lentiviral…”
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Regulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283
“The degree of immune response to a viral vector can be a consequence of one or more factors that include the method and route of vector delivery at the target site [208], cell-type-specific gene expression [209], and immunogenicity of the vector”
BackgroundImmunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Self-citationSalva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Metadata
- Authors
- Cordier, L., Gao, G.-P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., & Sweeney, H. L.
- Affiliations
- University of Pennsylvania (US)
- Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA 19104
- University of Chicago (US)
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2001-01-20
- Volume
- 12
- Issue
- 2
- Pages
- 205-215
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2174994066
- Cited by
- 152
- References
- 42
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 3 · 2015: 3 · 2014: 5 · 2013: 3 · 2012: 7
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
- Locations
- Human Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR/NS43648)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, gene therapy, muscular dystrophy, muscle-specific promoter, cytomegalovirus promoter, gamma-sarcoglycan, dystrophin-glycoprotein complex, humoral immune response, intramuscular injection, gene transfer
- MeSH terms
- Dependovirus, Animals, Antigen-Presenting Cells, beta-Galactosidase, Creatine Kinase, Cytoskeletal Proteins, Dendritic Cells, Genetic Vectors, Humans, Immunoenzyme Techniques, Macrophages, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Mutant Strains, Muscular Dystrophies, Promoter Regions, Genetic, T-Lymphocytes, Cytotoxic, Transduction, Genetic, Blotting, Western, Dystrophin, Gene Transfer Techniques, Muscle, Skeletal, Sarcoglycans, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.